Bacterial Pathogens Associated With Community-acquired Pneumonia in Children

Pediatric community acquired pneumonia (CAP) is one of the most common reasons for hospital admission, there is no reliable way of distinguishing the causative organism based on clinical features.

This study examined common pathogens of community-acquired pneumonia from 28 days up to 10 years in Dakahlia Governorate.

Study Overview

• Status: Completed
• Conditions: Children Chest Infection

• Study Type: Observational
• Enrollment (Actual): 100

Contacts and Locations

Study Locations

• Egypt
  • Gamasa, Egypt, 35712
    • Amira Hussin Mohammed

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Child
• Accepts Healthy Volunteers: N/A

• Sampling Method: Probability Sample

Study Population

A representative sample of 100 participants was taking by simple random sampling technique from children diagnosed to have community acquired pneumonia from Al Mansoura university hospital and Mansura International Hospital.

Description

- Inclusion criteria:

• Infants and children aged 28 days to ten years (male and female sexes).
• Patients diagnosed with community-acquired pneumonia.
• Pneumonia was diagnosed if the patient fulfilled has fever (temperature ≥38.3° C), Fast breathing (40 breaths per minute if the child is 1 year up to 10 years old), respiratory distress (tachypnea, retractions) and chest indrawing and cyanosis with compatible chest x-ray findings.

Exclusion criteria:

• Neonates
• Children more than 10 years
• Hospital acquired pneumonia
• Chronic lung disease, immunodeficiency and other congenital anomalies

Study Plan

How is the study designed?

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Complete blood count	From each participant, a sample of 4 ml of fresh venous blood was collected from the peripheral vein by the sterile venipuncture technique & drawn into a vacuumed purple top tube containing an anticoagulant. It was performed using a fully automated hematology analyzer. This test measures the amounts and sizes of red blood cells, hemoglobin, white blood cells, and platelets. It will be aggregated to arrive at one report. Hemoglobin is usually reported in units of grams per liter, or grams per deciliter. The analyzer counts red blood cells, reporting the result in units of 106 cells per microliter of blood or 1012 cells per liter, and measures their average size, which is called the mean cell volume and expressed in femtoliters or cubic micrometers. The total white blood cell count is usually reported in cells per microliter of blood, or 109 cells per liter. The platelet count can be reported in units of cells per microliter of blood, 103 cells per microliter, or 109 cells per liter.	At the baseline evaluation
C-reactive protein (CRP)	It was measured quantitatively in human serum by Beckman-Coulter AU Analyzers (USA). Sample preparation: 2 ml of blood in a sterile tube was centrifuged, then used immediately for CRP. C-reactive protein (CRP) is an annular (ring-shaped) pentameric protein found in blood plasma whose circulating concentrations rise in response to inflammation. Traditional CRP measurement only detected CRP in the range of 10 to 1,000 mg/L, whereas high-sensitivity CRP (hs-CRP) detects CRP in the range of 0.5 to 10 mg/L.	At the baseline evaluation
Blood culture and sensitivity on admission	It was done using the BD Bactec 9050 Blood Culture System (USA, Catalog No. 445800) instrument. A culture was considered positive if any organism was identified.	At the baseline evaluation
Gastric lavage culture or sputum culture on admission	It was inserted through the nose and down the stomach after nebulization with hypertonic saline at 5% for 10 seconds. Suction was applied for up to 15 seconds to collect the swallowed sputum in a sterile container. A culture was considered positive if any organism was identified.	At the baseline evaluation

Collaborators and Investigators

• Sponsor: Delta University for Science and Technology

Study record dates

Study Major Dates

• Study Start (Actual): January 1, 2021
• Primary Completion (Actual): August 31, 2021
• Study Completion (Actual): August 31, 2021

Study Registration Dates

• First Submitted: April 10, 2024
• First Submitted That Met QC Criteria: April 18, 2024
• First Posted (Actual): April 22, 2024

Study Record Updates

• Last Update Posted (Actual): June 11, 2024
• Last Update Submitted That Met QC Criteria: June 9, 2024
• Last Verified: June 1, 2024

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Infections; Respiratory Tract Infections; Respiratory Tract Diseases; Lung Diseases; Pneumonia
• Other Study ID Numbers: acquired pneumonia in children

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: UNDECIDED

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No